Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market
November 21, 2019 11:30 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002
November 21, 2019 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports Third Quarter 2019 Financial Results
November 15, 2019 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019
November 08, 2019 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors
October 15, 2019 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent
September 25, 2019 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 03, 2019 16:01 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
August 26, 2019 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports Second Quarter 2019 Financial Results
August 15, 2019 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Announce Second Quarter 2019 Financial Results on August 15, 2019
August 08, 2019 16:01 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...